Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol
In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks. Asthma symptom scores...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 1995-02, Vol.95 (2), p.541-547 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 547 |
|---|---|
| container_issue | 2 |
| container_start_page | 541 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 95 |
| creator | WASSERMAN, S. I FURUKAWA, C. T HENOCHOWICZ, S. I MARCOUX, J. P PRENNER, B. M FINDLAY, S. R GROSS, G. N HUDSON, L. D MYERS, D. J STEINBERG, P |
| description | In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks. Asthma symptom scores (daytime asthma, nighttime asthma, morning chest tightness, and cough) and peak expiratory flow rate were recorded daily on diary cards. Bronchial hyperresponsiveness was assessed by changes in diurnal variation in peak expiratory flow rate and by methacholine inhalation challenge. Statistically significant differences were found between groups favoring nedocromil sodium for relief of day and nighttime asthma and morning chest tightness. Patients treated with nedocromil sodium also had significantly lower diurnal variation in peak expiratory flow rate compared with patients treated with albuterol. Compared with patients treated with albuterol, patients treated with nedocromil sodium showed a greater improvement in cough and a decreased sensitivity to methacholine challenge. Patients in both groups reduced their as-needed albuterol use. Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol. The study also showed that more frequent use of a beta 2-agonist (for symptom relief or not) did not improve asthma control. Both drugs were well tolerated. |
| doi_str_mv | 10.1016/S0091-6749(95)70316-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16765160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16765160</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-179653e544713fcfc27c6fe479d2ee908613805f47e4ac0f7a2a20833bc270323</originalsourceid><addsrcrecordid>eNp1kc9u1DAQxi0EKkvhESr5gBA9hNpxbMfHqoKCVKkHytnyOpPGyH-C7bDaB-n7km1Xe-M0Gn2_mdF8H0IXlHyhhIqrn4Qo2gjZqc-KX0rCqGjIK7ShRMlG9C1_jTYn5C16V8pvsvasV2foTPa8FZJs0NN1qVMwuOzDXFMo2MQBG5d3Zo-n_Qw5Q5lTLO4vRCirnAH7tIOMhyW7-IhrBlMDxIp3rk44wpBsTsF5XNLgloDrZOJ_4AyPizcZuzgZD-tdv10q5OTfozej8QU-HOs5-vXt68PN9-bu_vbHzfVdYztKa0OlEpwB7zpJ2WhH20orRuikGloARXpBWU_42EnojCWjNK1pSc_YdiUJa9k5-vSyd87pzwKl6uCKBe9NhLQUTYUUnAqygvwFXH8rJcOo5-yCyXtNiT7EoZ_j0AevteL6OQ59mLs4Hli2AYbT1NH_Vf941E2xxo_ZROvKCWOd6Bnt2T-zkJbI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16765160</pqid></control><display><type>article</type><title>Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>WASSERMAN, S. I ; FURUKAWA, C. T ; HENOCHOWICZ, S. I ; MARCOUX, J. P ; PRENNER, B. M ; FINDLAY, S. R ; GROSS, G. N ; HUDSON, L. D ; MYERS, D. J ; STEINBERG, P</creator><creatorcontrib>WASSERMAN, S. I ; FURUKAWA, C. T ; HENOCHOWICZ, S. I ; MARCOUX, J. P ; PRENNER, B. M ; FINDLAY, S. R ; GROSS, G. N ; HUDSON, L. D ; MYERS, D. J ; STEINBERG, P</creatorcontrib><description>In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks. Asthma symptom scores (daytime asthma, nighttime asthma, morning chest tightness, and cough) and peak expiratory flow rate were recorded daily on diary cards. Bronchial hyperresponsiveness was assessed by changes in diurnal variation in peak expiratory flow rate and by methacholine inhalation challenge. Statistically significant differences were found between groups favoring nedocromil sodium for relief of day and nighttime asthma and morning chest tightness. Patients treated with nedocromil sodium also had significantly lower diurnal variation in peak expiratory flow rate compared with patients treated with albuterol. Compared with patients treated with albuterol, patients treated with nedocromil sodium showed a greater improvement in cough and a decreased sensitivity to methacholine challenge. Patients in both groups reduced their as-needed albuterol use. Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol. The study also showed that more frequent use of a beta 2-agonist (for symptom relief or not) did not improve asthma control. Both drugs were well tolerated.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/S0091-6749(95)70316-0</identifier><identifier>PMID: 7852670</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Administration, Inhalation ; Adolescent ; Adult ; Aged ; Albuterol - administration & dosage ; Albuterol - adverse effects ; Analysis of Variance ; Asthma - drug therapy ; Asthma - physiopathology ; Biological and medical sciences ; Bronchial Hyperreactivity - drug therapy ; Bronchial Hyperreactivity - physiopathology ; Bronchial Provocation Tests ; Child ; Double-Blind Method ; Female ; Forced Expiratory Volume - drug effects ; Humans ; Male ; Medical sciences ; Methacholine Chloride ; Middle Aged ; Nedocromil - administration & dosage ; Nedocromil - adverse effects ; Pharmacology. Drug treatments ; Respiratory system ; Statistics, Nonparametric ; Time Factors</subject><ispartof>Journal of allergy and clinical immunology, 1995-02, Vol.95 (2), p.541-547</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-179653e544713fcfc27c6fe479d2ee908613805f47e4ac0f7a2a20833bc270323</citedby><cites>FETCH-LOGICAL-c411t-179653e544713fcfc27c6fe479d2ee908613805f47e4ac0f7a2a20833bc270323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3468318$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7852670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WASSERMAN, S. I</creatorcontrib><creatorcontrib>FURUKAWA, C. T</creatorcontrib><creatorcontrib>HENOCHOWICZ, S. I</creatorcontrib><creatorcontrib>MARCOUX, J. P</creatorcontrib><creatorcontrib>PRENNER, B. M</creatorcontrib><creatorcontrib>FINDLAY, S. R</creatorcontrib><creatorcontrib>GROSS, G. N</creatorcontrib><creatorcontrib>HUDSON, L. D</creatorcontrib><creatorcontrib>MYERS, D. J</creatorcontrib><creatorcontrib>STEINBERG, P</creatorcontrib><title>Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks. Asthma symptom scores (daytime asthma, nighttime asthma, morning chest tightness, and cough) and peak expiratory flow rate were recorded daily on diary cards. Bronchial hyperresponsiveness was assessed by changes in diurnal variation in peak expiratory flow rate and by methacholine inhalation challenge. Statistically significant differences were found between groups favoring nedocromil sodium for relief of day and nighttime asthma and morning chest tightness. Patients treated with nedocromil sodium also had significantly lower diurnal variation in peak expiratory flow rate compared with patients treated with albuterol. Compared with patients treated with albuterol, patients treated with nedocromil sodium showed a greater improvement in cough and a decreased sensitivity to methacholine challenge. Patients in both groups reduced their as-needed albuterol use. Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol. The study also showed that more frequent use of a beta 2-agonist (for symptom relief or not) did not improve asthma control. Both drugs were well tolerated.</description><subject>Administration, Inhalation</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Albuterol - administration & dosage</subject><subject>Albuterol - adverse effects</subject><subject>Analysis of Variance</subject><subject>Asthma - drug therapy</subject><subject>Asthma - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Bronchial Hyperreactivity - drug therapy</subject><subject>Bronchial Hyperreactivity - physiopathology</subject><subject>Bronchial Provocation Tests</subject><subject>Child</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Forced Expiratory Volume - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methacholine Chloride</subject><subject>Middle Aged</subject><subject>Nedocromil - administration & dosage</subject><subject>Nedocromil - adverse effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory system</subject><subject>Statistics, Nonparametric</subject><subject>Time Factors</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQxi0EKkvhESr5gBA9hNpxbMfHqoKCVKkHytnyOpPGyH-C7bDaB-n7km1Xe-M0Gn2_mdF8H0IXlHyhhIqrn4Qo2gjZqc-KX0rCqGjIK7ShRMlG9C1_jTYn5C16V8pvsvasV2foTPa8FZJs0NN1qVMwuOzDXFMo2MQBG5d3Zo-n_Qw5Q5lTLO4vRCirnAH7tIOMhyW7-IhrBlMDxIp3rk44wpBsTsF5XNLgloDrZOJ_4AyPizcZuzgZD-tdv10q5OTfozej8QU-HOs5-vXt68PN9-bu_vbHzfVdYztKa0OlEpwB7zpJ2WhH20orRuikGloARXpBWU_42EnojCWjNK1pSc_YdiUJa9k5-vSyd87pzwKl6uCKBe9NhLQUTYUUnAqygvwFXH8rJcOo5-yCyXtNiT7EoZ_j0AevteL6OQ59mLs4Hli2AYbT1NH_Vf941E2xxo_ZROvKCWOd6Bnt2T-zkJbI</recordid><startdate>19950201</startdate><enddate>19950201</enddate><creator>WASSERMAN, S. I</creator><creator>FURUKAWA, C. T</creator><creator>HENOCHOWICZ, S. I</creator><creator>MARCOUX, J. P</creator><creator>PRENNER, B. M</creator><creator>FINDLAY, S. R</creator><creator>GROSS, G. N</creator><creator>HUDSON, L. D</creator><creator>MYERS, D. J</creator><creator>STEINBERG, P</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19950201</creationdate><title>Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol</title><author>WASSERMAN, S. I ; FURUKAWA, C. T ; HENOCHOWICZ, S. I ; MARCOUX, J. P ; PRENNER, B. M ; FINDLAY, S. R ; GROSS, G. N ; HUDSON, L. D ; MYERS, D. J ; STEINBERG, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-179653e544713fcfc27c6fe479d2ee908613805f47e4ac0f7a2a20833bc270323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Administration, Inhalation</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Albuterol - administration & dosage</topic><topic>Albuterol - adverse effects</topic><topic>Analysis of Variance</topic><topic>Asthma - drug therapy</topic><topic>Asthma - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Bronchial Hyperreactivity - drug therapy</topic><topic>Bronchial Hyperreactivity - physiopathology</topic><topic>Bronchial Provocation Tests</topic><topic>Child</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Forced Expiratory Volume - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methacholine Chloride</topic><topic>Middle Aged</topic><topic>Nedocromil - administration & dosage</topic><topic>Nedocromil - adverse effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory system</topic><topic>Statistics, Nonparametric</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WASSERMAN, S. I</creatorcontrib><creatorcontrib>FURUKAWA, C. T</creatorcontrib><creatorcontrib>HENOCHOWICZ, S. I</creatorcontrib><creatorcontrib>MARCOUX, J. P</creatorcontrib><creatorcontrib>PRENNER, B. M</creatorcontrib><creatorcontrib>FINDLAY, S. R</creatorcontrib><creatorcontrib>GROSS, G. N</creatorcontrib><creatorcontrib>HUDSON, L. D</creatorcontrib><creatorcontrib>MYERS, D. J</creatorcontrib><creatorcontrib>STEINBERG, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WASSERMAN, S. I</au><au>FURUKAWA, C. T</au><au>HENOCHOWICZ, S. I</au><au>MARCOUX, J. P</au><au>PRENNER, B. M</au><au>FINDLAY, S. R</au><au>GROSS, G. N</au><au>HUDSON, L. D</au><au>MYERS, D. J</au><au>STEINBERG, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>1995-02-01</date><risdate>1995</risdate><volume>95</volume><issue>2</issue><spage>541</spage><epage>547</epage><pages>541-547</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks. Asthma symptom scores (daytime asthma, nighttime asthma, morning chest tightness, and cough) and peak expiratory flow rate were recorded daily on diary cards. Bronchial hyperresponsiveness was assessed by changes in diurnal variation in peak expiratory flow rate and by methacholine inhalation challenge. Statistically significant differences were found between groups favoring nedocromil sodium for relief of day and nighttime asthma and morning chest tightness. Patients treated with nedocromil sodium also had significantly lower diurnal variation in peak expiratory flow rate compared with patients treated with albuterol. Compared with patients treated with albuterol, patients treated with nedocromil sodium showed a greater improvement in cough and a decreased sensitivity to methacholine challenge. Patients in both groups reduced their as-needed albuterol use. Regular treatment with nedocromil sodium therefore led to greater asthma symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol. The study also showed that more frequent use of a beta 2-agonist (for symptom relief or not) did not improve asthma control. Both drugs were well tolerated.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>7852670</pmid><doi>10.1016/S0091-6749(95)70316-0</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 1995-02, Vol.95 (2), p.541-547 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16765160 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Administration, Inhalation Adolescent Adult Aged Albuterol - administration & dosage Albuterol - adverse effects Analysis of Variance Asthma - drug therapy Asthma - physiopathology Biological and medical sciences Bronchial Hyperreactivity - drug therapy Bronchial Hyperreactivity - physiopathology Bronchial Provocation Tests Child Double-Blind Method Female Forced Expiratory Volume - drug effects Humans Male Medical sciences Methacholine Chloride Middle Aged Nedocromil - administration & dosage Nedocromil - adverse effects Pharmacology. Drug treatments Respiratory system Statistics, Nonparametric Time Factors |
| title | Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A26%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Asthma%20symptoms%20and%20airway%20hyperresponsiveness%20are%20lower%20during%20treatment%20with%20nedocromil%20sodium%20than%20during%20treatment%20with%20regular%20inhaled%20albuterol&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=WASSERMAN,%20S.%20I&rft.date=1995-02-01&rft.volume=95&rft.issue=2&rft.spage=541&rft.epage=547&rft.pages=541-547&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/S0091-6749(95)70316-0&rft_dat=%3Cproquest_cross%3E16765160%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16765160&rft_id=info:pmid/7852670&rfr_iscdi=true |